CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Up To Date
Latest News
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous...
TCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing...
Bavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese...
Switzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in...
Gilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare...